Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia

Official title

Phase II Study of Clofarabine and High-Dose Melphalan Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Myelodysplasia or Acute Leukemia in Remission

Study identification

NCT ID

NCT01885689

Recruitment status

Active, not recruiting

Study type

Interventional

Phase

Phase 2

Lead sponsor

City of Hope Medical Center

Other

Enrollment

72 participants

Conditions and interventions

Eligibility (public fields only)

Age range

18 Years to 75 Years

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Feb 9, 2014

Primary completion

Dec 26, 2019

Completion

Sep 20, 2026

Last update posted

Nov 13, 2025

2014 – 2026

United States locations

U.S. sites

1

U.S. states

1

U.S. cities

1

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Recently updated Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome trials

Other public records listing Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome. Sorted by last update posted; newest first. Not a recommendation.

• NCT04190550: Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia Active, not recruiting
• NCT03747757: Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue Active, not recruiting
• NCT03672539: Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome Active, not recruiting
• NCT03670966: 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome Recruiting
• NCT04284787: BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia Active, not recruiting
• NCT04214249: BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia Active, not recruiting

All Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome trials →